Expert Answers for Improving the Road to Remission with CAR T-Cell Therapies in Large B-Cell Lymphoma

Expert Answers to Common Questions for Improving the Road to Remission with CAR T-Cell Therapies in Large B-Cell Lymphoma: Considerations for Community Practice

ReachMD Healthcare Image
RestartResume

AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer, helping to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on CAR T-cell therapies in large B-cell lymphoma regarding practical considerations for CAR T-cell therapies.

Available credits: 0.25

Time to complete: 15 Minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    CD19-directed chimeric antigen receptor (CAR) T-cell therapies are revolutionizing the treatment of aggressive non-Hodgkin lymphoma (NHL), offering patients with refractory/relapsed disease the chance for a potential cure after a single infusion. However, the widespread use of CAR T-cell therapies faces several challenges, from the production of the therapies to the management of toxicities to issues of inpatient vs outpatient administration. While CAR T-cell therapies have historically been given in the inpatient setting, interest in outpatient delivery is growing, and this option may become more feasible if logistical issues and lack of multidisciplinary collaboration between the community provider and the CAR-T cell therapy center can be overcome.  

    AXIS routinely collects and analyzes data gathered from participants in our live activities. These questions provide incredible insight regarding the persistent challenges that clinicians face when trying to optimize treatment and management of patients with cancer, helping to verify where clinical practice gaps exist. This activity will provide expert answers to questions asked during a recent educational series on CAR T-cell therapies in large B-cell lymphoma regarding practical considerations for CAR T-cell therapies. 

  • Disclosure of Relevant Financial Relationships

    AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, peer reviewers, and other individuals who are in a position to control the content of this activity to disclose all personal financial relationships they may have in the past 24 months with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are identified and mitigated prior to initiation of the planning phase for an activity.  

    AXIS has mitigated and disclosed to learners all relevant financial relationships disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity. 

    The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: 

    The faculty, Caron A. Jacobson, MD, reported the following relevant financial relationships or relationships she has with ineligible companies of any amount during the past 24 months: Consultant: Kite/Gilead, AbbVie, Abintus Bio, ADC Therapeutics, Bristol-Myers Squibb/Celgene, Caribou Bio, Daiichi-Sankyo, Inc., ImmPACT Bio, Instil Bio, Ipsen Pharmaceuticals, Miltenyi, Morphosys, Novartis Pharmaceuticals Corporation, Synthekine. 

    The directors, planners, managers, peer reviewers, and relevant staff reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; Adrienne N. Nedved, MPA, PharmD, BCOP; and Melissa Duffy, PA-C hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Geist, MD, reported a financial interest/relationship or affiliation during the past 24 months as a past employee of Fresenius Medical Care. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months. 

  • Learning Objectives

    At the conclusion of this activity, participants should be better able to: 

    1. Identify patients with primary refractory disease or early relapse in aggressive non-Hodgkin lymphoma (NHL) who are eligible for chimeric antigen receptor (CAR) T-cell therapy 

    1. Develop strategies to improve outpatient delivery options for patients who are candidates for CAR T-cell therapy 

    1. Implement expert-recommended practices to mitigate and manage cytokine release syndrome, neurotoxicity, and related CAR T-cell toxicities 

  • Target Audience

    This educational activity is designed for community-based hematologists, medical oncologists, advanced practitioners, and other healthcare professionals who are part of the interprofessional team responsible for the therapeutic management of patients with large B-cell lymphoma (LBCL). 

  • Accreditation and Credit Designation Statements

    Accreditation Statement 
    In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team

    This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

     

    Credit Designation for Physicians 
    AXIS Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™Physicians should claim only the credit commensurate with theextent of their participation in the activity. 

    Credit Designation for Physician Assistants 

    AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits.  Approval is valid until 1/28/2025. PAs should only claim credit commensurate with the extent of their participation. 

    Credit Designation for Pharmacists 
    This knowledge-based activity is approved for 0.25 contact hour of continuing pharmacy education JA4008106-0000-24-002-H01-P. 

    Credit Designation for Nursing 
    AXIS Medical Education designates this continuing nursing education activity for 0.25 contact hour. 
    Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity. 

  • Commercial Support

    This activity is supported through an educational grant from Bristol Myers Squibb.

  • Disclaimer

    Disclosure of Unlabeled Use  
    This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information. 

    Disclaimer  
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying AXISMedEd…
but how about a more personalized experience?

Register for free